Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,580 signal articles · 330 in last 24h · 112,379 total before filter · latest 45m ago
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
AllMacro294Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: NVOSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
Insider Monkey43d agobullish
Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why

With an annual dividend yield of 3.75%, Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best NYSE Stocks to Buy for Dividends. Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark. On June 19, Nordea upgraded Novo Nordisk A/S (NYSE:NVO) from ‘Hold’ to ‘Buy’ and assigned the […]

Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)
Insider Monkey82d agoneutral
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating following the company’s Q1 2026 earnings report. On May 7, 2026, Lexicon Pharmaceuticals, Inc. […]

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show
24/7 Wall St.99d agoneutral
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
24/7 Wall St.100d agoneutral
Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?